Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
NCT04401475Phase 3Terminated
- Sponsor
- Edesa Biotech, Inc.
- Start
- Nov 2020
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of paridiprubart in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Edesa Biotech, Inc.. Started Nov 2020; status: terminated.
02
Drugs
paridiprubart
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04401475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401475.